





EVIDENCE BASED PRACTICE: PROGESTERONE IN THREATENED AND RECURRENT MISCARRIAGE

Associate Prof Dr Shilpa Nambiar MD MRCOG MRCPI Advanced Fellowship Maternal Medicine PU- RCSI School of Medicine Prince Court Medical Centre



Recurrent Miscarriage

- Defined as 3 or more pregnancy losses up to 24 weeks /viability
- Affects 1% couples
- Multiple risk factors- age, genetic factors, anatomical factors, medical disorders/thrombophilia
- Only unexplained will be addressed here








Threatened Miscarriage


- Defined in bleeding in a viable pregnancy with a closed cervix
- Happens in 15-20% of pregnancies
- Half result in pregnancy loss
- Those that don't have a higher risk of preterm delivery, low birthweight and perinatal death















'Women with idiopathic recurrent miscarriage may benefit from the immunomodulatory properties of progesterone in early pregnancy.'



EIGO	Cochrane Database of Systematic Reviews Progestogen for preventing miscarriage New search Review Intervention David M Haas M, Patrick S Ramsey First published: 31 October 2013	
• 14 trials	(2158 women)	
 No statistically significant reduction of miscarriages between progesterone or placebo Subgroup analysis of those with recurrent miscarriages 		
	rials(225 women) gnificant reduction of miscarriage rate (OR 0.39; 95% CI 0.21 -0.72)	
No differ	rence in route of administration	
No differ	rence in rate of PTB, neonatal death, fetal genital anomalies	











The PROMISE trial (UK) STUDY DESIGN


1568 WOMEN RANDOMISED


836 CONCEIVED NATURALLY

404 PROGESTERONE 432 PLACEBO


LIVE BIRTH RATE 65.8% VS 63.3% NO SIGNIFICANT DIFFERENCE


PROGESTERONE STARTED AFTER POSITIVE PREGNANCY TEST

















ORIGINAL ARTICLE: EARLY PREGNANCY


Luteal start vaginal micronized progesterone improves pregnancy success in women with recurrent pregnancy loss


Mary D. Stephenson, M.D., M.Sc., a,b Dana McQueen, M.D., M.A.S., a Michelle Winter, M.D., b and Harvey J. Kliman, M.D., Ph.D. c


^a University of Illinois Recurrent Pregnancy Loss Program, Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, Illinois; ^b University of Chicago, Chicago, Illinois; and ^c Department of Obstetrics, Gynecology and Reproductive Sciences, Reproductive and Placental Research Unit, Yale University School of Medicine, New Haven, Connecticut

The use of luteal start vaginal micronized P (*Utrogestan*[°] vaginal capsules 100mg - 200mg BID) was associated with improved pregnancy success in a strictly defined cohort of women with RPL










PRISM TRIAL RECRUITMENT CENTRES

Airedale General Hospital, Steeton Birmingham Heartlands Hospital Birmingham Women's Hospital Bradford Royal Infirmary Burnley General Hospital, East Lancashire Chelsea and Westminster Hospital, London Cumberland Infirmary, Carlisle Derriford Hospital, Plymouth East Surrey Hospital, Redhill Glasgow Royal Infirmary Guys and St Thomas Hospitals, London Hinchingbrooke Hospital, Huntingdon Hull Royal Infirmary James Cook University Hospital, South Tees John Radcliffe Hospital, Oxford Kings College Hospital, London Liverpool Women's Hospital Musgrove Park Hospital, Taunton New Cross Hospital, Wolverhampton North Devon District Hospital, Barnstaple North Tyneside General Hospital Princess Royal Hospital, Telford Queen Alexandra Hospital, Portsmouth Queen's Hospital, Burton Queen's Medical Centre, Nottingham Royal Devon and Exeter Hospital Royal Hallamshire Hospital, Sheffield Royal Infirmary of Edinburgh Royal London Hospital Royal Preston Hospital

Royal Stoke University Hospital Royal Victoria Infirmary, Newcastle Scunthorpe General Hospital St James University Hospital, Leeds St Mary's Hospital, Manchester St Mary's Hospital, London St Michael's University Hospital, Pristol St Peter's Hospital, Chertey Sunderland Royal Hospital University College Hospital University Hospital, Coventry Walsall Manor Hospital Warrington Hospital West Middlesex University Hospital, London Whispo Cross University Hospital, London Whiston Hospital, Moresyida, Money Worcestershire Royal Hospital, Worcester

UNIVERSITY OF COLLEGE OF

he role of progesterone in threatened miscarriage





PRISM - Aim and Objectives

Primary aim

PRISM will test the hypothesis that in women presenting with vaginal bleeding in the first trimester progesterone (Utrogestan **400 mg vaginal capsules, twice** daily) started as soon as possible after a scan has demonstrated a visible intrauterine gestation sac and continued to 16 completed weeks of gestation, compared with placebo **increases maternities with live births beyond 34 completed weeks by at least 5%.**



